Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Cass
I
I
Kuo
D Y
DY
Fields
A L
AL
Runowicz
C D
CD
Goldberg
G L
GL
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010976:Platelet Count; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000150:complications; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D019772:Topotecan